Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal cancer: a phase I study.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509135-17-00

Acronym

PIPAC Nal-IRI

Enrollment

Registered

2023-12-13

Start date

2022-11-18

Completion date

Unknown

Last updated

2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

appendix, cholangiocarcinoma), irresectable peritoneal metastases (PM) originating from gastrointestinal (GI) cancer (colorectal, pancreatic, Patients with advanced, small bowel, stomach

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Belgium

Outcome results